Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2005-07-12
2011-11-08
Ha, Julie (Department: 1654)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C435S170000
Reexamination Certificate
active
08052978
ABSTRACT:
A method for preparing a soluble antigenic extract fromRhodococcus equiis disclosed. The method includes a step of solubilizing membranes of said bacteria by contacting said bacteria with an extraction solution containing a nonionic detergent of sorbitan polyethylene fatty acid ester type. Also disclosed is a soluble antigenic extract obtainable by said preparation method, said extract including membrane antigens ofRhodococcus equidissolved in the extraction solution. Finally, a composition including the soluble antigenic extract as a medicine is disclosed, including preferably a nanoparticulate or oil-in-water emulsion type adjuvant, and the use of the soluble antigenic extract for preparing a pharmaceutical composition for preventing or treating aRhodococcus equi-induced infection in an animal.
REFERENCES:
patent: 4803070 (1989-02-01), Cantrell et al.
patent: 6579524 (2003-06-01), Corradin et al.
patent: 2002/0058040 (2002-05-01), Grimes et al.
patent: 2125426 (1995-12-01), None
patent: WO 90/14837 (1990-12-01), None
patent: WO 94/15636 (1994-07-01), None
patent: WO 98/41188 (1998-09-01), None
patent: WO 99/30737 (1999-06-01), None
patent: WO 99/56776 (1999-11-01), None
patent: WO 00/25812 (2000-05-01), None
patent: WO 00/71077 (2000-11-01), None
patent: WO 00/71154 (2000-11-01), None
patent: WO 02/096386 (2002-12-01), None
patent: WO 03/087021 (2003-10-01), None
ATCC33701 information from www.atcc.org, pp. 1-2. Accessed May 14, 2009.
ATCC6939 information from www.atcc.org, pp. 1-2. Accessed May 14, 2009.
Rhodococcus equiinformation from http://emedicine.medscape.com/article/235466-overview, pp. 1-5. Accessed May 14, 2009.
Skolnick J, Fetrow JS, “From genes to protein structure and function: novel applications of computational approaches in the genomic era,” Trends in Biotech., 2000, 18(1): 34-39.
Becu et al., “Immunopropylaxis ofRhodococcus equipneumonia in foals,” Veterinary Microbiology, 1997, 56, 193-204.
Benoit et al., “H2O2, Which Causes Macrophage-Related Stress, Triggers Induction of Expression of Virulence-Associated Plasmid Determinants inRhodococcus equi,” Infection and Immunity, Jul. 2002, 70(7), 3768-3776.
Benoit et al., “Introduction ofvapgenes encoded by the virulence plasmid ofRhodococcus equiduring acid tolerance response,” Res. Microbiol., 2001, 152, 439-449.
Higuchi et al., “Clinical evaluation of the serodiagnostic value of enzyme-likned immunosorbent assay forRhodococcus equiinfection in foals,” Equine Veterinary Journal, 1997, 29(4), 274-278.
Kossovsky et al., “Surface-Modified Diamond Nanoparticles as Antigen Delivery Vehicles,” Bioconjugate Chemistry, Sep./Oct. 1995, 6(5), 507-511.
Mueller et al., “Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art,” European Journal of Pharmaceutics and Biopharmaceutics, 2000, 50, 161-177.
Prescott et al., “Use ofRhodococcus equivirulence-associated protein for immunization of foals againstR equipneumonia,” Am. J. Vet. Res., Apr. 1997, 58(4), 356-359.
Takai et al., “Immunoglobulin and Specific Antibody Responses toRhodococcus(Corynebacterium)equiInfection in Foals as Measured by Enzyme-Linked Immunosorbent Assay,” J. Clin. Microbiology, May 1986, 23(5), 943-947.
Tan et al., “Molecular Characterization of a Lipid-modified Virulence-associated Protein ofRhodococcus equiand its Potential in Protective Immunity,” Can. J. Vet. Res., 1995, 59, 51-59.
Taouji et al., “Serum and mucosal antibodies of infected foals recognized two distince epitopes of VapA ofRhodococcus equi” FEMS Immunology and Medical Microbiology, 2002, 34, 299-306.
Taouji et al., “Immunogenecity of synthetic peptides representing linear B-cell epitopes of VapA ofRhodococcus equi,” Vaccine, 2004, 22, 1114-1123.
Vanniasinkam et al., “B-Cell Epitope Mapping of the VapA Protein ofRhodococcus equi: Implications for Early Detection ofR. equiDisease in Foals,” J. Clin. Microbiology, Apr. 2001, 39(4), 1633-1637.
Varga et al., “Prevention ofRhodococcus equipneumonia of foals using two different inactivated vaccines,” Veterinary Microbiology, 1997, 56, 205-212.
Verschoor et al., “Comparison of Immunity Generated by Nucleic Acid-, MF59-, and ISCOM-Formulated Human Immunodeficiency Virus Type 1 Vaccines in Rhesus Macaques: Evidence for Viral Clearance,” J. Virology, Apr. 1999, 73(4), 3292-3300.
Cauchard et al., “Foal IgG and opsonizing anti-Rhodococcus equiantibodies after immunization of pregnant mares with a protective VapA candidate vaccine,”Veterinary Microbiology, vol. 104, pp. 73-81, 2004.
Ballet Jean Jacques
Cauchard Julien
Taouji Saïd
Agence National de Securite Sanitaire de l'Alimentation, de l'En
Foley & Lardner LLP
Ha Julie
LandOfFree
Vaccine composition against Rhodococcus equi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccine composition against Rhodococcus equi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine composition against Rhodococcus equi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4304278